In 2021 and 2022, Sabatini was fired from the Howard Hughes Medical Institute and resigned his positions at the Whitehead Institute and the Massachusetts Institute of Technology, following allegations of sexual harassment.[2][3][4] Sabatini denies the allegations.
Biography
David M. Sabatini was born and raised in New York to David D. Sabatini and Zulema Sabatini, both Argentine immigrants from Buenos Aires. He obtained his B.S. from Brown University followed by both his MD and his Ph.D. at Johns Hopkins School of Medicine, where he worked in the lab of Solomon H. Snyder. He joined the Whitehead Institute as a Whitehead Fellow in 1997, the same year he graduated from Johns Hopkins.[5] In 2002 he became an assistant professor at MIT and a Member of the Whitehead Institute. He was promoted to tenured professor in 2006.
Sabatini is the scientific founder of Navitor,[7] Raze Therapeutics,[8] and KSQ Therapeutics.[9]
Allegations of sexual misconduct
In April 2021, after a new director of the Whitehead Institute where Sabatini worked had initiated a sexual harassment survey, a former graduate student at the institute came forward with sexual harassment allegations against him.[10]
In August 2021, following an investigation of the complaints by an outside law firm, Sabatini was forced to resign from the Whitehead Institute and was fired from the Howard Hughes Medical Institute which had funded his research.[11][2][12] Sabatini denies that the alleged behavior was sexual harassment, claims that the investigation was biased, and has filed a defamation lawsuit against the Whitehead Institute, its director and his accuser.[3][10][4] His accuser responded with a countersuit, claiming that he coerced her into sex and that the atmosphere in his lab was sexually charged and toxic.[10]
MIT placed Sabatini on administrative leave while it conducted its own investigation.[13] This investigation concluded that Sabatini had violated its policies on sexual relationships in the workplace, finding that he "engaged in a sexual relationship with a person over whom he held a career-influencing role", and gave a recommendation to revoke tenure. Sabatini resigned from his position at MIT in April 2022.[3][13]
In 2022, Sabatini was under consideration for a position at the NYU Grossman School of Medicine.[14] After significant protests from students and some faculty over the sexual harassment allegations, he withdrew his name from consideration.[4][15][16]
Independent funding and IOCB Prague
In February 2023, Bill Ackman and an unnamed partner announced $25 million to fund Sabatini's research, though it is unclear if he could successfully find an institution willing to host his lab or if one could be built independently.[17][18] By November 2023, Sabatini had accepted a position at the Institute of Organic Chemistry and Biochemistry (IOCB) of the Czech Academy of Sciences in Prague,[19][20] and in April 2024 it was announced that IOCB would open a Boston branch, where it was planned that Sabatini would spend part of his time.[21]
Scientific contributions
As a graduate student in Solomon Snyder's Lab at Johns Hopkins, Sabatini began working on understanding the molecular mechanism of rapamycin; a macrolide antibiotic discovered in the soil of Easter Island that has potent antifungal, immunosuppressive, and anti-tumorigenic properties.[5] Although the TOR/DRR genes had been identified in 1993 as conferring rapamycin resistance in budding yeast, the direct target of rapamycin and its mechanism of action in mammals was unknown.[22][23] In 1994, Sabatini used rapamycin and its binding partner FKBP12 to purify the mechanistic Target of Rapamycin (mTOR) protein from rat brain, showing it to be the direct target of rapamycin in mammals and the homolog of the yeast TOR/DRR genes.[5]
Since starting his own lab at the Whitehead Institute in 1997, Sabatini has made numerous key contributions to the understanding of mTOR function, regulation, and importance in diseases such as cancer.[24] For example, his lab discovered the mTORC1[25] and mTORC2[26] multi-protein complexes, the nutrient sensing Rag GTPase pathway upstream of mTORC1,[27] as well as the direct amino acid sensors Sestrin[28][29] and CASTOR.[30][31]
Sabatini's research interests have expanded in recent years to include cancer metabolism as well as technology development surrounding the use of high-throughput genetic screens in human cells, most notably through the use of RNA interference[32] and the CRISPR-Cas9 system.[33]
Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH (1994). "RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs". Cell. 78 (1): 35–43. doi:10.1016/0092-8674(94)90570-3. PMID7518356. S2CID33647539.
References
^Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH (July 1994). "RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs". Cell. 78 (1): 35–43. doi:10.1016/0092-8674(94)90570-3. PMID7518356. S2CID33647539.
^Kunz J, Henriquez R, Schneider U, Deuter-Reinhard M, Movva NR, Hall MN (1993). "Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression". Cell. 73 (3): 585–96. doi:10.1016/0092-8674(93)90144-f. PMID8387896. S2CID42926249.
Arsenault, Mark; Irons, Meghan E.; Wen, Patricia (January 28, 2023). "Fate and the fallen star". Spotlight. The Boston Globe. Part 1, Part 2. Retrieved February 12, 2023
.jpg)
